抗血小板药物的合理应用(二) 被引量：4

Rational Application of Antiplatelet Drugs

下载PDF

导出

摘要心、脑血管疾病是导致人类死亡的主要病因,动脉粥样硬化血栓形成是心、脑血管疾病的病理基础,其中血小板激活和聚集在其形成过程中起核心作用。抗血小板治疗有助于减少心、脑血管不良事件的发生。根据循证医学的要求,重点介绍目前临床应用较多的5类抗血小板药物中的4个代表性药物,包括其适应证、用法用量、注意事项和联合用药等。 Cardia and cerebrovascular disorder is the mare cause of a alsease which, rom is pathology foundation that the activation and collection of platelet play core effect.So antiplatelet cure conduce to reduce the harmful events of cardia and cerebrovascular disorder：The article focus on introduce 4 representative medicines of 5 medicineS product were major appliced in current clinical according to the requisition of evidence-based medine, inclding indication, usage, dosage, announcements, alliance medication, et,al.

作者孙忠实朱珠肖燕萍

机构地区北京海军总医院北京协和医院北京妇产医院

出处《中国药物警戒》 2007年第5期297-302,共6页 Chinese Journal of Pharmacovigilance

关键词抗血小板药阿司匹林氯吡格雷阿那格雷噻氯匹定合理应用 antiepileptic drugs asprine clopidogrel ticlopidine anagrelide rational application

分类号 R916.691 [医药卫生—药学] R969.3 [医药卫生—药理学]

引文网络
相关文献

参考文献6

1孙忠实,朱珠.抗血小板药物研究进展(一)[J].引进国外医药技术与设备,1999,5(7):33-37. 被引量：4
2Jeffrey S. Berger,Maria C. Roncaglioni,Fausto Avanzini,Ierta Pangrazzi,Gianni Tognoni,David L. Brown,崔艳丽（译）,赵秀丽（校）.阿斯匹林在男性和女性心血管事件一级预防中的应用——随机对照试验性别特异性汇总分析[J].美国医学会杂志（中文版）,2006,25(5):275-282. 被引量：40
3李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量：193
4规范应用阿司匹林治疗缺血性脑血管病的专家共识[J].中华内科杂志,2006,45(1):81-82. 被引量：76
5柯元南.急性冠状动脉综合征诊断和治疗进展[J].中华老年心脑血管病杂志,2006,8(1):2-4. 被引量：23
6HE Wenxuan,1, 2 REN Tianying,1, 21. Oregon Hearing Research Center, Department of Otolaryngology and Head & Neck Surgery, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, NRC04, Portland, Oregon 97239 USA,2. School of Medicine, Xi’an Jiaotong University, Xi’an, Shaanxi 710061 China.Backward Propagation of Otoacoustic Emissions[J].Journal of Otology,2006,1(1):40-44. 被引量：4

二级参考文献68

1Antithrombotic Trialists′ Collaboration.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death,myocardial infarction,and stroke in high risk patients.BMJ,2002,324:71-86.
2Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events.The SALT Collaborative Group.Lancet,1991,338:1345-1349.
3European Stroke Prevention Study 2.Efficacy and safety data.J Neurol Sci,1997,151 Suppl:S1-S77.
4Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke.EAFT (European Atrial Fibrillation Trial) Study Group.Lancet,1993,342:1255-1262.
5Ridker PM,Cook NR,Lee IM,et al.A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women.N Engl J Med,2005,352:1293-1304.
6The International Stroke Trial (IST):a randomised trial of aspirin,subcutaneous heparin,both,or neither among 19435 patients with acute ischaemic stroke.International Stroke Trial Collaborative Group.Lancet,1997,349:1569-1581.
7CAST:randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke.CAST (Chinese Acute Stroke Trial) Collaborative Group.Lancet,1997,349:1641-1649.
8Braunwald E, Mark DB, Jones RH, et al. Unstable angina: diagnosis and management (P). Rockvilles MD: Agency for Health care Policy and Research and the National Heart, Lung, and Blood Institute, US Public Health Service. US Department of tiealth and Human Services,1994:1. AHCPR Publication. No 94-0602.
9Menown IB, Mackenzie G, Adgey AA. Optimizing the initial 12-lead electrocardiographic diagnosis of acute myocardial infarction [ J ]. Eur Heart J,2000,21:275-283.
10Antman EM,Anbc DT,Armstrong PW, et al. ACC/AHA Guideline for the management of patients with ST-elevation myocardial infarction-executive summary. A report of the ACC/AHA Task Force on Practice Guidelines (Writing Committee to revise the 1999 Guideline) for the Management of Patients with Acute Myocardial Infarction [ J ]. JACC,2004,44:671-719.